Bayer Closes EUR 3 Billion LARC Financing as Pipeline Wins and Roundup Ruling Hang in the Balance

Bayer closes a roughly EUR 3 billion minority investment in its LARC unit with Apollo and KKR, keeping control as it funds its turnaround.

Bayer has finalized a structured equity arrangement for its long-acting reversible contraceptive (LARC) business, with funds and entities managed by Apollo joining KKR as a significant minority investor. The pair are injecting roughly EUR 3 billion — equivalent to USD 3.46 billion — into the unit, following an agreement first flagged on July 10.

Under the deal, the LARC operations are folded into a new operating entity in which the financial investors hold a stake. Bayer, however, keeps both the entrepreneurial majority and full operational control, and the business remains fully consolidated within group accounts. Nothing about the existing strategy for the product line is set to change.

The transaction drew a heavyweight advisory roster. Deutsche Bank, BofA and Linklaters worked on Bayer's side, while Apollo enlisted Centerview, Latham & Watkins, Paul Weiss and NautaDutilh. Apollo separately reiterated its intention to invest more than USD 100 billion in Germany over the coming decade.

Investors greeted the completion with measured optimism, nudging the stock up 0.4% to EUR 48.89 on the day.

A Balance Sheet Buffer While the Turnaround Runs

The capital injection hands the Leverkusen-based pharma and agriculture group extra breathing room as it presses ahead with its restructuring. In its 2025 financial year, Bayer reported revenue of EUR 45.6 billion with a workforce of around 88,000. The shares have climbed 32% since the start of the year.

Fresh clarity on the LARC front comes alongside other fundamental catalysts that continue to command market attention. On the pharmaceutical side, the active ingredient sevabertinib — marketed as Hyrnuo — secured FDA approval last Thursday as an initial treatment option for HER2-mutant non-squamous non-small cell lung cancer (NSCLC). Japan had already granted marketing authorization across all lines of therapy a few weeks earlier. Roughly two weeks ago, Bayer also filed for Japanese approval of Kerendia (finerenone) in non-diabetic chronic kidney disease, backed by positive Phase 3 data.

Those operational strides are reshaping the investment case. Where legal legacy issues dominated perceptions in recent months, the pipeline's substance is regaining weight. Barclays responded last Friday by lifting its price target on the stock from EUR 60 to EUR 70 with a buy rating. The market has already begun to reflect the brighter tone: the shares trade at EUR 49.26, up 33% year to date.

The Question That Matters

Whether revenue contributions from new products like Hyrnuo and Kerendia can grow quickly enough to shoulder the looming financial obligations from the planned glyphosate settlement — without crimping the wider group's room to maneuver — is now the pivotal issue for the share price.

In the bullish reading, Hyrnuo ramps up swiftly into a dependable oncology revenue driver after its US and Japanese clearances. A smooth US launch would put Bayer in front of a patient group with substantial unmet need, and a first-line designation widens the market opportunity considerably compared with follow-on approvals alone. Add a mid-term label expansion for Kerendia in non-diabetic chronic kidney disease, and the pharma division's revenue profile broadens further.

On the legal flank, a favorable outcome would deliver planning certainty. The proposed class settlement over the Roundup weedkiller provides for payments of up to USD 7.25 billion, disbursed over as long as 21 years in declining, capped annual tranches. Should the competent US court grant final approval following last Monday's hearing, Bayer's annual cash burden would become calculable and stretched over time. Barclays sees the combination of operational momentum and gradual legal resolution as grounds for a further push toward the EUR 70 mark.

What Could Go Wrong

Residual legal uncertainty is the chief risk. The hearing on final approval of the multibillion-dollar settlement took place last Monday, but a binding ruling has yet to be handed down. If the court withholds final consent or demands amendments, the sword of pending US litigation would swing back with full force, leaving the financial exposure unforeseeable and the legal calm the market hopes for on hold.

Operational execution risk compounds the picture. Regulatory clearance does not guarantee commercial success: Hyrnuo must hold its own in the competitive US market, and reimbursement terms with health systems still need negotiating. A sluggish revenue ramp for Hyrnuo, or delays to Kerendia's Japanese approval, would pit fixed obligations to clear legacy liabilities against a weaker-than-hoped cash inflow — and the recent share price recovery could fizzle out.

The Road Ahead

So long as the market trusts in judicial confirmation of the settlement and Hyrnuo's US rollout proceeds on schedule, the stock's upward trend stays intact. Reaching Barclays' EUR 70 target, though, presupposes that formal legal approval is granted and no major new risks emerge. If the court rejects the USD 7.25 billion settlement, the valuation discount is likely to widen again quickly.

The next real test of operating health lands on November 3, 2026, when Bayer publishes its third-quarter statement. That report will show how pharmaceutical sales are developing in the current business and how management sizes up the financial burdens for the remaining months.